main webpage
W Topic
Acute Promyelocytic Leukemia
The Lancet Neurology • Vol 23 • No 9
Endovascular thrombectomy for acute ischaemic stroke with established large infarct (TENSION): 12-month outcomes of a multicentre, open-label, randomised trial
2024
European Union Horizon 2020 Research and Innovation Programme.
Article

Acute Promyelocytic Leukemia

Subtype of acute myeloid leukaemia characterised by accumulation of promyelocytes

Acute promyelocytic leukemia ( APML , APL ) is a subtype of acute myeloid leukemia (AML), a cancer of the white blood cells. In APL, there is an abnormal accumulation of immature granulocytes called promyelocytes. The disease is characterized by a chromosomal translocation involving the retinoic acid receptor alpha ( RARA ) gene and is distinguished from other forms of AML by its responsiveness to all- trans retinoic acid (ATRA; also known as tretinoin) therapy. Acute promyelocytic leukemia was first characterized in 1957 by French and Norwegian physicians as a hyperacute fatal illness, with a median survival time of less than a week.

Exploring foci of:
The Lancet Neurology • Vol 23 • No 9
Endovascular thrombectomy for acute ischaemic stroke with established large infarct (TENSION): 12-month outcomes of a multicentre, open-label, randomised trial
2024
European Union Horizon 2020 Research and Innovation Programme.
Click Acute Promyelocytic Leukemia Vs:
Acute Necrotizing Ulcerative Gingivitis
Acute Myeloid Leukemia
Acute Kidney Injury
Acute Coronary Syndrome
Acute Radiation Syndrome
Acute Lymphoblastic Leukemia
Acute Stress Reaction
Acute Disseminated Encephalomyelitis
Acute Liver Failure
Click Acute Promyelocytic Leukemia Vs:
Acute Intermittent Porphyria
Acute Pancreatitis
Acute Respiratory Distress Syndrome
Acute Bronchitis